Welcome to the Anavex Life Sciences’ Fiscal 2022 Fourth Quarter Conference Call. My name is Clint Tomlinson, and I’ll be your host for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference is being recorded. The call will also be available for replay on Anavex’s website at www.anavex.com. With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Sandra Boenisch, Principal Financial Officer. Before we begin, please note that during this conference call, the Company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the Company’s filings with the SEC. This includes, without limitation, the Company’s Forms 10-K and 10-Q which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. And with that, I’d like to turn the call over to Dr. Missling.

Thank you, Clint. We appreciate everyone joining us on today's conference call to review our most recently reported financial results and to provide a business update. We are excited with the continued advancement of our lead product candidate ANAVEX 2-73 in Alzheimer's disease and Rett syndrome. As we maintain our attention on execution across each of our clinical programs and overall business operations, we are planning to present top line data of the randomized, double-blind, placebo-controlled Phase 2b/3 study ANAVEX 2-73-AD-004 for the treatment of early Alzheimer disease in a late breaking oral presentation at the upcoming clinical trials on Alzheimer disease, CTAD Congress 2022 on December 1, 2022 at 4:30 PM Pacific Time in San Francisco, California. In our Rett syndrome program, we are nearing completion of the randomized, placebo-controlled EXCELLENCE Phase 2/3 study for the treatment of pediatric patients with Rett syndrome. We expect to update on the complete enrollment accordingly. Earlier this month, we announced that the FDA granted Orphan Drug Designation to ANAVEX 2-73 for the treatment of Fragile X syndrome. Fragile X syndrome is the most common form of inherited intellectual disability and the most frequent single gene cause of autism spectrum disorder with an estimated population of approximately 62,500 in the U.S. and over 1 million worldwide. Recent guidance received from the FDA confirms our strategy to advance ANAVEX 2-73 for the treatment of Fragile X syndrome in our double-blind, randomized, placebo-controlled Phase 2/3 development program. We will share more details about this clinical program as it becomes available. In August, we reported a relevant new peer-reviewed publication in the journal Science Translational Medicine titled “Widespread cell stress and mitochondrial dysfunction occurs in patients with early Alzheimer disease.” This publication provided further scientific evidence of the relevance of sigma-1 receptor activation as a compensatory mechanism to chronic CNS diseases. Further pipeline expansion of the Anavex platform using gene biomarkers of response, applying precision medicine for neurological disorders with unmet medical need is expected, including; meeting with the FDA to discuss the ANAVEX 2-73 Parkinson disease program, including a pivotal Phase 3 study; a planned initiation of ANAVEX 2-73 imaging-focused Parkinson disease clinical trial sponsored by the Michael J. Fox Foundation; a planned initiation of a Phase 2/3 clinical trial for the treatment of a new rare disease indication; and a planned initiation of ANAVEX 3-71 Phase 2 clinical trial for schizophrenia. And now, I would like to direct the call to Sandra Boenisch, Principal Financial Officer of Anavex for a brief financial summary of the recently reported quarter.

Thank you, Christopher, and good morning, everyone. During our fourth fiscal quarter, we reported a net loss of $14.3 million or $0.18 per share. The reported net loss includes $6 million in non-cash items. Our research and development expenses for the quarter were $11.4 million as compared to $9.4 million for the comparable quarter of fiscal 2021. General and administrative expenses were $3.9 million compared to $2.9 million for the comparable quarter of fiscal 2021. Our cash position on September 30, 2022 was $149.2 million. During the full fiscal year 2022, we utilized cash and cash equivalents of $24.2 million to fund our operations. Within our current cash utilization range, we believe we have a sufficient cash runway to fund operations and clinical programs beyond the next four years. The overall increase in expenses over the comparable period is primarily related to the expansion of our team, and an associated increase in non-cash charges period over period. Thank you. And now, I'll return the call back to you, Christopher.

Thank you, Sandra. This is an exciting time in neuroscience and rare disease drug development, and we remain on track for the readout of the placebo-controlled ANAVEX 2-73 Phase 2b/3 Alzheimer's disease clinical trial, a condition of significant unmet need and economic burden for which there are only limited approved pharmacological treatment options, as well as initiating biomarker-driven precision medicine clinical studies as planned. I would like now to turn the call back to Clint for Q&A.

Thank you, Chris. We'll now begin the question and answer session. And our first question is coming from Charles Duncan from Cantor Fitzgerald.

Congrats on the progress in the quarter. I had a couple of questions with regard to the AD top line that you're planning to talk about towards the end of this week. I guess I'm wondering, what would define success for you? And can you help us understand the enrollment criteria for those patients? Was it primarily a clinical diagnosis of Alzheimer's or was there some imaging or some other confirmation for those patients being Alzheimer's?

A good question. So let me address this. The requirement for enrollment into the study required AD pathology, which was assessed by physician assessment of criteria of Alzheimer's pathology as well as, if available, PET scan or a spinal tap confirmation of the presence in the patient.

Okay. And then defining success, obviously, statistical significance is one thing. But what would you like to do with the data and what could be next steps?

I think it really depends on the data. I would refer to waiting for Thursday to then be able to respond more properly to this question.

Okay. And then moving on to the EXCELLENCE study. In terms of the endpoint, can you help us understand what is the endpoint that you're most focused on? Is it RSBQ AUC in Rett? Or is it the Clinical Global Impression of Improvement?

It's really both. So the RSBQ is the assessment of the parents and the CGI-I is the assessment by the physician. So both are relevant and they should actually match or correlate with each other. And so we believe both endpoints are critical.

And can we anticipate readout from that study in, say, the first quarter of the coming year?

I would say the first half since we have to finish the trial, which is 12 weeks long. If we complete the enrollment this quarter, which we expect to, and we are on track to do that, we would need to add 12 weeks. So it will be then in the first half.

Our next call is from Soumit Roy from Jones Trading.

Congratulations on all the progress and certainly a big quarter for Anavex. On the Alzheimer data that's coming up next Thursday, could you give us a little detail like how the data will be presented? Is it the primary endpoint? Would you combine the two high-dose and median dose arm and then look versus placebo, or each of the arms will be individually assessed against placebo? And are they powered enough to show us like 20% improvement? How is it going to look like when we see the press release?

Yes, I would really recommend to wait for the data on the 1st of December. And we just have powered the study according to our knowledge from previous clinical trials. So we think we are in good shape. I would recommend to wait for December 1.

Got it. That's completely understandable. I have a quick question. Can you share what percentage of patients agreed to undergo either the scan or CNS tap to examine additional biomarkers?

I don't have that information right now. We'll need to wait until December 1 for more details.

The next question comes from Yun Zhong at BTIG.

So a follow-up question on the Alzheimer's data. And I know it's probably difficult to speculate what the data will look like. But Christopher, can you talk about your plan if the study meets the primary endpoint? Or if the study fails to meet the primary endpoint, what sort of plan on individual scenarios, please?

Again, I would comment just to recommend to wait for December 1. It's not a good point today to speculate on that. We are very close. So I think it's best to discuss it when the data is there. We always know that the FDA responds best when there's existing data to discuss. So that's my recommendation.

Okay. Then maybe a question on the cash runway guidance. The full year runway is very encouraging. But does that include a potential additional Alzheimer's study if you need to do another one, please?

Guidance is really based on the historical advancement of our cash utilization rate, which was always very consistent over the last years. So it's an extrapolation, if you so like. So it's a conservative extrapolation, so with the increase. And it has definitely all the studies which we have planned to initiate and execute included in that budget.

Okay. Last question to confirm the Parkinson's disease program. So there is a possibility that the next study that you conduct in Parkinson's disease will be a pivotal study based on your discussion with the FDA?

We are aiming for that. We have very strong evidence from the PDD study that the effect on MDS-UPDRS, which is the main primary endpoint of this indication has been very favorable with ANAVEX 2-73. So the plan would be to make sure we are able to move forward as quickly as possible. That would mean to aim for a Phase 3.

I don't see any further questions at this time. Dr. Missling?

So thank you again. We are very much looking forward, and we're very excited about the company's potential as we build on biomarker-driven precision medicine studies with significant unmet medical need and economic burden. And we're looking forward to clinical trial readouts in autism disease and pediatric Rett syndrome. Thank you.

Thank you, ladies and gentlemen. This concludes today's conference call, and we thank you for participating. Have a great week.